C4 Therapeutics, Inc. (CCCC) Tops Q1 EPS by 5c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q1 EPS of ($0.20), $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.15 million versus the consensus estimate of $4.8 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• JPMorgan Starts Multi Commodity Exchange of India Ltd (MCX:IN) at Underweight
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)